-
Article
Open AccessNeoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted ther...
-
Article
Consensus statement on the surveillance of patients with gastrointestinal malignancies
Improvements in early detection, screening and treatment of cancer have resulted in a significant improvement in cancer mortality and an increase in the number of cancer survivors globally. Accordingly, a sign...
-
Article
Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
Paclitaxel plus ramucirumab is a standard second-line regimen for patients with advanced gastric adenocarcinoma, but clinical benefit remains modest. One potential resistance mechanism to VEGFR2 inhibition is ...
-
Article
Virtual oncology clinics during the COVID-19 pandemic
The COVID-19 pandemic has resulted in radical changes in the delivery of healthcare worldwide. Our oncology service (at an Irish national cancer centre) rapidly transitioned to the use of telemedicine or virtu...
-
Article
Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study
Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during the gestational period (gp-PABC) or in the first postpartum year (pp-PABC). Despite its infrequent occurrence, the inciden...
-
Chapter
The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer
While esophageal cancer is an uncommon cancer in the USA, it is endemic in other parts of the world, especially East Asia. Adenocarcinomas of the lower esophagus and gastroesophageal junction now account for m...
-
Chapter
Immunotherapy in Esophageal Cancer
Targeting of the immune checkpoints cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death (PD)-1/PD-ligand 1 (PD-L1) with monoclonal antibodies has been shown to improve outcomes in a number of solid ...
-
Article
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein
-
Article
Duration of Adjuvant Chemotherapy in Colon Cancer: Current Standards and New Updates
Adjuvant therapy for 6 months is the standard of care for stage III colon cancer. The use of oxaliplatin-based therapy over fluoropyrimidine alone increases toxicity, including dose-dependent peripheral neurop...
-
Article
Where youth matters—clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer
Young women with breast cancer (YWBC) represent 7–12% of breast cancer diagnoses and ostensibly have more biologically aggressive subtypes with higher relapse and mortality rates. We studied the clinical and path...
-
Article
Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases
Liver metastases are the commonest cause of death for patients with colorectal cancer. Growing evidence supports the use of selective internal radiation therapy (SIRT) in combination with conventional chemothe...
-
Chapter
Neoadjuvant and Adjuvant Therapy
Recent years have seen advances in the management of esophageal cancer, which have led to clinically meaningful improvements in outcome. While surgical resection is the mainstay of treatment for locally advanc...
